In this issue:
Adjuvant pembrolizumab vs placebo in resected stage III melanoma
Encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF-mutant melanoma
Cancer immunotherapy efficacy and patients’ sex
Neoadjuvant plus adjuvant dabrafenib and trametinib vs standard of care in patients with high-risk, surgically resectable melanoma
Risk stratification tool for melanoma
Association of BMI and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy or chemotherapy
Outcomes of SRS + pembrolizumab for melanoma brain metastases
Rechallenge with BRAF-directed treatment in metastatic melanoma
Please login below to download this issue (PDF)